Aligning the care delivered with the patient's own desires is the biggest opportunity available to drive costs down while improving quality, according to Marc Boutin, JD, chief executive officer of the National Health Council.
With more than 35,000 people expected to attend the 2015 ASCO Annual Meeting, there are many highly anticipated aspects of the conference; however, Peter P. Yu, MD, FACP, FASCO, president of ASCO and director of Cancer Research at Palo Alto Medical Foundation, highlighted how the society has been going in a different direction with its keynote speaker.
Introduced with good intent, some of the provisions of the Orphan Drug Act may compel the FDA to rethink its strategy.
A review of the benefit design choices made by states that expanded Medicaid (as of the end of 2014), revealed that states are offering more generous coverage that what is required under federal law, according to researchers with The Commonwealth Fund.


Improved survivorship rates among cancer patients has brought a growing awareness of a serious latent impact of chemotherapy and radiation: cardiotoxicity. Despite extensive research on the subject, our understanding of the tools for identifying and preventing these complications is limited.
To promote collaboration and efficiency, the MD Anderson Cancer Center developed an interdisciplinary team–based Heart Success Program to coordinate the management of concurrent cardiomyopathy and HF while the patient is receiving cancer treatment.
Medical monitoring and counseling can help us track and contain many harmful effects of cancer drug-induced cardiotoxicity. Patient engagement from the very beginning, along with medically advanced testing methods, can help us surmount cardiotoxicity and better ensure that patients receive only the benefits of essential cancer treatment.
With the explosion of new therapies in cancer care, the risk of each new therapy must be clearly understood prior to making treatment decisions with patients. Data from clinical trials alone are insufficient to educate these treatment choices, and real-world evidence from higher-risk populations should be generated to inform these treatment decisions.


Most Popular

AJMC Strategic Alliance